Schizophrenia Research
Volume 120, Issue 1 , Pages 217-224 , July 2010

Cognitive remediation therapy in schizophrenia: Cost-effectiveness analysis

  • Anita Patel

      Affiliations

    • Centre for the Economics of Mental Health, Health Service and Population Research Department, Box 24, Institute of Psychiatry, King's College London, De Crespigny Park, London SE5 8AF, United Kingdom
    • ,
  • Martin Knapp

      Affiliations

    • Centre for the Economics of Mental Health, Health Service and Population Research Department, Box 24, Institute of Psychiatry, King's College London, De Crespigny Park, London SE5 8AF, United Kingdom
    • Personal Social Services Research Unit, London School of Economics and Political Science, Houghton Street, London WC2A 2AE, United Kingdom
    • ,
  • Renee Romeo

      Affiliations

    • Centre for the Economics of Mental Health, Health Service and Population Research Department, Box 24, Institute of Psychiatry, King's College London, De Crespigny Park, London SE5 8AF, United Kingdom
    • Corresponding Author InformationCorresponding author. Tel.: +44 20 7848 0588; fax: +44 20 7848 0458.
    • ,
  • Clare Reeder

      Affiliations

    • Department of Psychology, Box 77, Institute of Psychiatry, King's College London, De Crespigny Park, London SE5 8AF, United Kingdom
    • ,
  • Pall Matthiasson

      Affiliations

    • Section of Neuroimaging, Box 67, Institute of Psychiatry, King's College London, De Crespigny Park, London SE5 8AF, United Kingdom
    • ,
  • Brian Everitt

      Affiliations

    • Department of Biostatistics and Computing, Box 20, Institute of Psychiatry, King's College London, De Crespigny Park, London SE5 8AF, United Kingdom
    • ,
  • Til Wykes

      Affiliations

    • Department of Psychology, Box 77, Institute of Psychiatry, King's College London, De Crespigny Park, London SE5 8AF, United Kingdom

Received 4 June 2009 ,Revised 26 October 2009 ,Accepted 3 December 2009.

References 

  1. Andrews G, Sanderson K, Corry J, Issakidis C, Lapsley H. Cost-effectiveness of current and optimal treatment for schizophrenia. Br. J. Psychiatry. 2003;183:427–435
  2. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ. 1997;6(4):327–340
  3. Bryson G, Bell M. Initial and final work performance in schizophrenia: cognitive and symptom predictors. J. Nerv. Ment. Dis. 2003;191:87–92
  4. Chisholm D, Knapp MRJ, Knudson HC, Amaddeo F, Gaite L, van Wijngaarden B the Epsilon Study Group. Client socio-demographic and service receipt inventory — European Version: development of an instrument for international research. Epsilon Study 5. Br. J. Psychiatry. 2000;39:s28–s33Suppl
  5. Curtis L. Unit costs of health and social care. Canterbury: University of Kent; 2008;
  6. Delahunty A, Reeder C, Wykes T. Revised cognitive remediation therapy manual. London: Institute of Psychiatry; 2002;
  7. Gray R, Leese M, Bindman J, Becker T, Burti L, David A, et al. Adherence therapy for people with schizophrenia: European multicentre randomised controlled trial. Br. J. Psychiatry. 2006;189:508–514
  8. Healey A, Knapp M, Astin J, Beecham J, Kemp R, Kirov G, et al. Cost-effectiveness evaluation of compliance therapy for people with psychoses. Br. J. Psychiatry. 1998;172(5):420–424
  9. Kay SR, Fizbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987;13:261–276
  10. Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr. Bull. 2004;30:279–293
  11. Kuipers E, Fowler D, Garety P, Chishom D, Freeman D, Dunn G, et al. London-east Anglia randomised controlled trial of cognitive-behavioural therapy for psychosis. III: Follow-up and economic evaluation at 18months. Br. J. Psychiatry. 1998;173:61–68
  12. McGurk SR, Twamley EW, Sitzer DI, McHugo GJ, Mueser KT. A meta-analysis of cognitive remediation in schizophrenia. Am. J. Psychiatry. 2007;164:1791–1802
  13. OECD, 2001. OECD 515 statistics on purchasing power parities (http://www.oecd.org/std/ppp).
  14. Patel A, Everitt B, Knapp M, Reeder C, Grant D, Ecker C, et al. Schizophrenia patients with cognitive deficits: factors associated with costs. Schizophr. Bull. 2006;32:766–785
  15. Penn DL, Waldheter EJ, Perkins DO, Mueser KT, Lieberman JA. Psychosocial treatment for first-episode psychosis: a research update. Am. J. Psychiatry. 2005;162:2220–2232
  16. Reeder C, Newton E, Frangou S, Wykes T. Which executive skills should we target to affect social functioning and symptom change? A study of a cognitive remediation therapy program. Schizophr. Bull. 2004;30(1):87–100
  17. Sturm R, Unützer J, Katon W. Effectiveness research and implications for study design: sample size and statistical power. Gen. Hosp. Psychiatry. 1999;21(4):274–283
  18. van Hout BA, Al MJ, Gordon GS, Rutten FF. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ. 1994;3:309–319
  19. Wechsler D. Wechsler Adult Intelligence Scale: Revised. New York: Harcourt, Brace, Jovanovich; 1981;
  20. Wykes T, Reeder C, Williams C, Corner J, Rice C, Everitt B. Are the effects of cognitive remediation therapy (CRT) durable? Results from an exploratory trial in schizophrenia. Schizophr. Res. 2003;61:163–174
  21. Wykes T, Reeder C, Landau S, Everitt B, Knapp M, Patel A, et al. Cognitive remediation therapy in schizophrenia. Randomised controlled trial. Br. J. Psychiatry. 2007;190:421–427

PII: S0920-9964(09)00593-3

doi: 10.1016/j.schres.2009.12.003

Schizophrenia Research
Volume 120, Issue 1 , Pages 217-224 , July 2010

Article Tools

* Image Usage & Resolution